Jigar Raythatha
Partner @ Third Rock Ventures
Boston, United States
Jigar Raythatha is a Series B investor at Third Rock Ventures in Boston focused on Health Care and Life Science. Jigar Raythatha is based out of Boston, Massachusetts and is the Partner of Third Rock Ventures. Jigar previously worked at Jounce Therapeutics, Inc as a Chair of the Board of Directors. Jigar Raythatha attended the Columbia Business School.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Jigar Raythatha invests in
Stages Jigar Raythatha invests in
Countries Jigar Raythatha invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (50%)
- Life Science 1 (50%)
- Biotechnology 1 (50%)
Stage
- Series B 1 (50%)
- Series C 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M / Series C / Jun 30, 2026 | ||
| Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $123M / Series B / Mar 22, 2023 |
Co-Investors
About Third Rock Ventures
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.
Third Rock Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Cary Pfeffer
Partner
|
|||
|
Jeff Tong
Partner
|
|||
|
Jigar Raythatha
Partner
|
|||
Mark Levin
Partner
|
|||
Reid Huber
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jigar Raythatha invest in?
Jigar Raythatha invests primarily in Health Care, Life Science and Biotechnology startups, most often at Series B and Series C stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jigar Raythatha?
Public channels for Jigar Raythatha include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jigar Raythatha last invest?
The most recent investment recorded for Jigar Raythatha closed in Jun 2026. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
